FDA and EMA see Novartis’s Kymriah as an option for patients with relapsed or refractory B-cell ALL and DLBCL

FDA and EMA see Novartis’s Kymriah as an option for patients with relapsed or refractory B-cell ALL and DLBCL

January 17, 2018 Off By Dino Mustafić

The FDA has set Novartis’s Kymriah suspension injection for  patients who have relapsed or refractory diffuse large B-cell lymphona (DLBCL) and can’t have certain stem cell translplant (ASCT), for the Priority Review.

Novartis on Wednesday said that that its supplemental Biologics License Application (sBLA) for Kymriah who are ineligible for or relapse after autologous stem cell transplant (ASCT) has been accepted for the Priority Review. Also, the European Medicines Agency (EMA) has granted accelerated assessment to the Marketing Authorization Application (MAA) for Kymriah for the treatment of children and young adults with r/r B-cell acute lymphoblastic leukemia (ALL) and for adult patients with r/r DLBCL who are ineligible for ASCT.

Priority Review and accelerated assessment are granted to therapies which may provide a significant improvement in the safety and effectiveness of the treatment of a serious disease, and the designations are intended to expedite the standard review time. If approved by the FDA and EMA, Kymriah would represent the first chimeric antigen receptor T cell (CAR-T) therapy available for two distinct indications in non-Hodgkin lymphoma and B-cell ALL.

Kymriah became the first CAR-T cell therapy to receive regulatory approval when it was approved by the FDA in August 2017 for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

Samit Hirawat, MD, Head, Novartis Oncology Global Drug Development, said: “The first approval of a CAR-T therapy truly redefined the future of the cancer treatment landscape, and we are only at the beginning of this new era in cancer care. The Priority Review designation and accelerated assessment signal that the FDA and EMA have recognized the potential of Kymriah to provide a much-needed therapeutic option for these patients with relapsed or refractory B-cell ALL and DLBCL.”

Oxford BioMedica also noted that it is the sole manufacturer of the lentiviral vector that encodes CTL019. The Group signed an agreement with Novartis in July 2017 for the commercial and clinical supply of lentiviral vectors used to generate CTL019 and other undisclosed CAR-T products, for which Oxford BioMedica could potentially receive in excess of $100m from Novartis over the next three years. Oxford BioMedica also noted that, according to a deal from October 2014, it will also receive undisclosed royalties on potential future sales of Novartis CAR-T products.

Novartis about Kymriah

Kymriah is a novel immunocellular therapy and a one-time treatment that uses a patient’s own T cells to fight cancer. Kymriah uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular expansion and persistence. In 2012, Novartis and the University of Pennsylvania (Penn) entered into a global collaboration to further research, develop and commercialize CAR-T cell therapies, including Kymriah, for the investigational treatment of cancers.